26.54
-0.24 (-0.90%)
| Previous Close | 26.78 |
| Open | 26.86 |
| Volume | 1,027,221 |
| Avg. Volume (3M) | 773,592 |
| Market Cap | 1,526,915,200 |
| Price / Earnings (TTM) | 8.56 |
| Price / Earnings (Forward) | 6.13 |
| Price / Sales | 2.02 |
| Price / Book | 1.99 |
| 52 Weeks Range | |
| Earnings Date | 28 Oct 2025 |
| Profit Margin | 20.50% |
| Operating Margin (TTM) | 30.45% |
| Diluted EPS (TTM) | 2.62 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 18.90% |
| Total Debt/Equity (MRQ) | 24.63% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | 222.67 M |
| Levered Free Cash Flow (TTM) | 143.41 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 24.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Harmony Biosciences Holdings, I | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -1.5 |
| Price Volatility | 3.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 1.30 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.10% |
| % Held by Institutions | 92.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Valor Management Llc | 30 Jun 2025 | 6,618,033 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 107.23%) | Buy |
| Median | 41.00 (54.48%) | |
| Low | 35.00 (Mizuho, 31.88%) | Buy |
| Average | 43.00 (62.02%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 28.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 25 Sep 2025 | 36.00 (35.64%) | Buy | 27.04 |
| HC Wainwright & Co. | 25 Sep 2025 | 55.00 (107.23%) | Buy | 27.04 |
| Mizuho | 25 Sep 2025 | 35.00 (31.88%) | Buy | 27.04 |
| Needham | 24 Sep 2025 | 41.00 (54.48%) | Buy | 26.76 |
| Truist Securities | 21 Jul 2025 | 48.00 (80.86%) | Buy | 35.25 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Sep 2025 | Announcement | Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome |
| 26 Aug 2025 | Announcement | Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress |
| 21 Aug 2025 | Announcement | Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference |
| 05 Aug 2025 | Announcement | Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025 |
| 22 Jul 2025 | Announcement | Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025 |
| 15 Jul 2025 | Announcement | Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |